Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

被引：0
|
作者：
Holland C Detke
Fangyi Zhao
Michael M Witte
机构：
[1] Eli Lilly and Company,
[2] Lilly USA,undefined
[3] LLC,undefined
来源：
BMC Psychiatry | / 12卷
关键词：
Olanzapine; Long-acting injection; Pamoate; Haloperidol; Effect size; Onset; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
    David P McDonnell
    Holland C Detke
    Richard F Bergstrom
    Prajakti Kothare
    Jason Johnson
    Mary Stickelmeyer
    Manuel V Sanchez-Felix
    Sebastian Sorsaburu
    Malcolm I Mitchell
    BMC Psychiatry, 10
  • [32] Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
    McDonnell, David P.
    Detke, Holland C.
    Bergstrom, Richard F.
    Kothare, Prajakti
    Johnson, Jason
    Stickelmeyer, Mary
    Sanchez-Felix, Manuel V.
    Sorsaburu, Sebastian
    Mitchell, Malcolm I.
    BMC PSYCHIATRY, 2010, 10
  • [33] Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
    Holland C Detke
    David P McDonnell
    Elizabeth Brunner
    Fangyi Zhao
    Sebastian Sorsaburu
    Victoria J Stefaniak
    Sara A Corya
    BMC Psychiatry, 10
  • [34] Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
    Ciudad, Antonio
    Anand, Ernie
    Berggren, Lovisa
    Casillas, Marta
    Schacht, Alexander
    Perrin, Elena
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1737 - 1750
  • [35] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Joseph Peuskens
    Vibeke Porsdal
    Jan Pecenak
    Peter Handest
    Yulia D'yachkova
    Radim Brousil
    Walter Deberdt
    BMC Psychiatry, 12
  • [36] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Peuskens, Joseph
    Porsdal, Vibeke
    Pecenak, Jan
    Handest, Peter
    D'yachkova, Yulia
    Brousil, Radim
    Deberdt, Walter
    BMC PSYCHIATRY, 2012, 12
  • [37] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, D.
    Ascher-Svanum, H.
    Bertsch, J.
    Detke, H.
    Mcdonnell, D.
    Witte, M.
    Haro, J.
    VALUE IN HEALTH, 2011, 14 (07) : A288 - A289
  • [38] AN OPEN, RANDOMIZED, CONTROLLED COMPARISON OF LONG-ACTING INJECTABLE RISPERIDONE VS. ORAL OLANZAPINE IN SCHIZOPHRENIA & SCHIZOAFFECTIVE DISORDER
    Keks, Nicholas A.
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S5 - S5
  • [39] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, Diego
    Ascher-Svanum, Haya
    Bertsch, Jordan
    Detke, Holland C.
    McDonnell, David
    Maria Haro, Josep
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S357 - S357
  • [40] Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    Inoue, Yuichi
    Takaya, Atsuhiko
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (04) : 405 - 406
12345